Soliqua 100/33 regulatory update

FDA approved an NDA from Sanofi for Soliqua 100/33 insulin glargine/lixisenatide to treat Type II diabetes. The pharma plans to launch the product in January 2017. Sanofi used a Priority Review voucher, for which it paid $245 million in 2015, to speed Soliqua’s review (see BioCentury, June 1, 2015). ...